Twist Bioscience (TWST) | Financial Analysis & Statements
Twist Bioscience Corporation Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Sep 2025Income Metrics
Revenue
99.0M
Gross Profit
50.8M
51.35%
Operating Income
-29.9M
-30.23%
Net Income
-27.1M
-27.41%
EPS (Diluted)
$-0.45
Balance Sheet Metrics
Total Assets
641.9M
Total Liabilities
168.9M
Shareholders Equity
473.0M
Debt to Equity
0.36
Cash Flow Metrics
Operating Cash Flow
-14.5M
Free Cash Flow
-24.2M
Revenue & Profitability Trend
Quarter Income Flow
Sep 30, 2025
Annual Income Flow
2025
Twist Bioscience Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 376.6M | 313.0M | 245.1M | 203.6M | 132.3M |
| Cost of Goods Sold | 185.6M | 179.6M | 155.4M | 119.3M | 80.6M |
| Gross Profit | 191.0M | 133.3M | 89.7M | 84.2M | 51.7M |
| Gross Margin % | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% |
| Operating Expenses | |||||
| Research & Development | 80.3M | 90.9M | 106.9M | 120.3M | 69.1M |
| Selling, General & Administrative | 247.0M | 218.4M | 189.7M | 212.9M | 135.9M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 327.3M | 309.2M | 296.6M | 333.3M | 205.0M |
| Operating Income | -136.3M | -175.9M | -206.9M | -249.0M | -153.3M |
| Operating Margin % | -36.2% | -56.2% | -84.4% | -122.3% | -115.8% |
| Non-Operating Items | |||||
| Interest Income | 11.4M | 15.3M | 14.4M | 3.1M | 435.0K |
| Interest Expense | - | 29.0K | 5.0K | 80.0K | 367.0K |
| Other Non-Operating Income | 47.9M | -47.6M | -10.9M | 17.8M | -836.0K |
| Pre-tax Income | -77.0M | -208.2M | -203.5M | -228.3M | -154.0M |
| Income Tax | 719.0K | 560.0K | 1.2M | -10.4M | -1.9M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -77.7M | -208.7M | -204.6M | -217.9M | -152.1M |
| Net Margin % | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% |
| Key Metrics | |||||
| EBITDA | -160.3M | -131.8M | -163.9M | -230.5M | -144.4M |
| EPS (Basic) | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 |
| EPS (Diluted) | $-1.30 | $-3.60 | $-3.60 | $-4.04 | $-3.15 |
| Basic Shares Outstanding | 59808000 | 58016000 | 56885000 | 53885000 | 48251000 |
| Diluted Shares Outstanding | 59808000 | 58016000 | 56885000 | 53885000 | 48251000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Twist Bioscience Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 183.0M | 226.3M | 286.5M | 378.7M | 465.8M |
| Short-term Investments | 49.4M | 50.1M | 49.9M | 126.3M | 12.0M |
| Accounts Receivable | 57.0M | 34.9M | 44.1M | 40.3M | 26.5M |
| Inventory | 28.3M | 24.1M | 32.1M | 39.3M | 31.8M |
| Other Current Assets | 15.2M | 11.4M | 11.7M | 11.9M | 8.3M |
| Total Current Assets | 333.0M | 346.8M | 424.3M | 596.5M | 546.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 151.0M | 158.4M | 176.0M | 137.2M | 110.0M |
| Goodwill | 177.8M | 186.1M | 226.1M | 231.4M | 63.1M |
| Intangible Assets | 13.4M | 14.5M | 54.5M | 59.7M | 18.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 7.3M | 5.9M | 8.5M | 5.0M | 6.2M |
| Total Non-Current Assets | 308.9M | 267.5M | 352.1M | 364.9M | 155.6M |
| Total Assets | 641.9M | 614.3M | 776.4M | 961.4M | 702.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 11.1M | 1.6M | 14.1M | 20.1M | 14.9M |
| Short-term Debt | 13.8M | 14.8M | 14.9M | 13.6M | 9.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 722.0K | 961.0K | 430.0K | 12.6M | 6.1M |
| Total Current Liabilities | 91.4M | 71.0M | 73.3M | 90.7M | 63.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 61.8M | 70.2M | 79.2M | 81.3M | 53.2M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 747.0K | 407.0K | 475.0K | 60.0K | 5.1M |
| Total Non-Current Liabilities | 77.5M | 70.6M | 79.6M | 81.3M | 58.2M |
| Total Liabilities | 168.9M | 141.6M | 153.0M | 172.0M | 121.3M |
| Equity | |||||
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -1.3B | -1.2B | -1.0B | -828.4M | -610.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 473.0M | 472.7M | 623.4M | 789.4M | 580.8M |
| Key Metrics | |||||
| Total Debt | 75.6M | 85.0M | 94.1M | 94.9M | 62.9M |
| Working Capital | 241.6M | 275.8M | 350.9M | 505.8M | 483.4M |
Balance Sheet Composition
Twist Bioscience Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -77.7M | -208.7M | -204.6M | -217.9M | -152.1M |
| Depreciation & Amortization | 24.9M | 31.4M | 29.3M | 16.5M | 9.8M |
| Stock-Based Compensation | 64.5M | 50.9M | 30.3M | 79.7M | 37.0M |
| Working Capital Changes | -12.2M | 2.7M | 1.7M | -5.1M | -10.4M |
| Operating Cash Flow | 1.6M | -121.7M | -146.6M | -119.5M | -113.3M |
| Investing Activities | |||||
| Capital Expenditures | -28.0M | -5.1M | -27.8M | -101.9M | -27.1M |
| Acquisitions | 2.5M | 0 | 0 | -13.9M | -483.0K |
| Investment Purchases | -49.4M | -51.9M | -76.3M | -217.6M | -58.8M |
| Investment Sales | 50.1M | 53.9M | 154.7M | 100.5M | 242.5M |
| Investing Cash Flow | -24.8M | -3.1M | 50.6M | -238.7M | 156.2M |
| Financing Activities | |||||
| Share Repurchases | -16.0K | -4.0M | -4.4M | -7.8M | -10.8M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | 0 | 0 | -1.6M | -3.3M |
| Financing Cash Flow | 15.0M | -4.0M | -4.4M | 260.5M | 309.7M |
| Free Cash Flow | -75.6M | -69.2M | -170.3M | -226.2M | -139.3M |
| Net Change in Cash | -8.2M | -128.7M | -100.4M | -97.7M | 352.5M |
Cash Flow Trend
Twist Bioscience Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-45.26
Forward P/E
-33.53
Price to Book
8.49
Price to Sales
9.90
PEG Ratio
8.00
Profitability Ratios
Profit Margin
-19.56%
Operating Margin
-31.73%
Return on Equity
-16.79%
Return on Assets
-13.49%
Financial Health
Current Ratio
3.78
Debt to Equity
24.79
Beta
2.21
Per Share Data
EPS (TTM)
$-1.27
Book Value per Share
$7.44
Revenue per Share
$6.50
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TWST | 3.6B | -45.26 | 8.49 | -16.79% | -19.56% | 24.79 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Revvity | 9.7B | 45.77 | 1.46 | 3.22% | 8.45% | 46.87 |
| Icon plc | 9.0B | 15.52 | 0.94 | 6.27% | 7.40% | 38.26 |
| Charles River | 8.3B | 681.33 | 2.61 | -4.23% | -3.60% | 81.95 |
Financial data is updated regularly. All figures are in the company's reporting currency.





